Jeremy Starkweather - Medigus Director
| MDGSDelisted Stock | USD 2.36 0.18 8.26% |
Director
Mr. Jeremy Shane Starkweather will no longer serve as Director of Sales and MarketingUnited States at Medigus Ltd effective December 31, 2016. He has held this role since June 1, 2015. His work experience includes the following roles Vice PresidentSales Business Development at Xlumena Inc for one and a half years, Manager of Marketing Business Development at Boston Scientific Corporation for two years and Senior Product Manager at Boston Scientific Corporation for fourteen months. He holds a Bachelor of Business Administration degree from Oral Roberts University.
| Age | 42 |
| Phone | 972 73 370 4691 |
| Web | https://www.medigus.com |
Medigus Management Efficiency
The company has return on total asset (ROA) of (0.0663) % which means that it has lost $0.0663 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3072) %, meaning that it created substantial loss on money invested by shareholders. Medigus' management efficiency ratios could be used to measure how well Medigus manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| James Coyne | STRATA Skin Sciences | N/A | |
| Kristina Wright | Paragon 28 | 47 | |
| Marco Taglietti | Delcath Systems | 57 | |
| Simon Pedder | Delcath Systems | 56 | |
| Laura Philips | Delcath Systems | 56 | |
| Dennis Langer | Delcath Systems | 62 | |
| Michael Mashaal | ReShape Lifesciences | 42 | |
| Brian Dempsey | Paragon 28 | 36 | |
| Rox Anderson | STRATA Skin Sciences | N/A | |
| Jose Bedoya | SurModics | 61 | |
| Brian Larkin | Dynatronics | 48 | |
| Gavriel Magen | BrainsWay | 54 | |
| Thomas Bowers | Paragon 28 | 70 | |
| Nathaniel Woodson | Paragon 28 | 72 | |
| Scott Klosterman | Dynatronics | 59 | |
| Susan Harnett | Paragon 28 | 57 | |
| Avraham Posen | BrainsWay | 47 | |
| Susan Knight | SurModics | 63 | |
| Scott Ward | Dynatronics | 61 | |
| Kenneth Ludlum | IRIDEX | 63 | |
| Carl Florio | Paragon 28 | 64 | |
Management Performance
| Return On Equity | -0.31 | ||||
| Return On Asset | -0.0663 |
Medigus Ltd ADR Leadership Team
Elected by the shareholders, the Medigus' board of directors comprises two types of representatives: Medigus inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Medigus. The board's role is to monitor Medigus' management team and ensure that shareholders' interests are well served. Medigus' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Medigus' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ilan Oren, Executive Officer | ||
| Efrat Venkert, External Director | ||
| Anat Naschitz, Director | ||
| Yaron Silberman, Chief Ltd | ||
| Ori Hershkovitz, External Director | ||
| Yair Rabinovitch, Director | ||
| Menashe Sonnenschein, Vice President - Operations | ||
| Gilad Mamlok, CFO | ||
| Christopher Rowland, CEO and Director | ||
| Eitan Machover, Independent Director | ||
| Minelu Sonnenschein, VP of Operations | ||
| Oded Yatzkan, Director of Fin. and Accounting and VP | ||
| Nissim Darvish, Chairman of the Board | ||
| Jeremy Starkweather, Director of Sales, Director of Marketing-United States | ||
| Yuval Yanai, Director | ||
| Aviel Shapira, Medical Director | ||
| Yair Rabinowitch, Director | ||
| Liron Carmel, Chief Officer | ||
| Erez Haimovitz, Director | ||
| Tali Dinar, Chief Officer | ||
| Doron Birger, Director | ||
| Tatyana Yossef, Controller | ||
| Yaron Zilberman, Vice President - Sales and Marketing |
Medigus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Medigus a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.31 | ||||
| Return On Asset | -0.0663 | ||||
| Profit Margin | (0.13) % | ||||
| Operating Margin | (0.09) % | ||||
| Current Valuation | 65.3 M | ||||
| Shares Outstanding | 1.89 M | ||||
| Shares Owned By Institutions | 0.29 % | ||||
| Number Of Shares Shorted | 4.18 K | ||||
| Price To Earning | 33.86 X | ||||
| Price To Book | 0.15 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Medigus Ltd ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the Medigus Ltd ADR information on this page should be used as a complementary analysis to other Medigus' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Other Consideration for investing in Medigus Stock
If you are still planning to invest in Medigus Ltd ADR check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Medigus' history and understand the potential risks before investing.
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |